3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
5
Withdrawn
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
66
Gastrointestinal
30
Tumor-Agnostic
5
Thoracic
5
Head & Neck
5
Gynecologic
4
Lymphoid
3
Plasma cell
2
Other hematologic neoplasm
2
CNS
2
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Doxorubicin
25
Cyclophosphamide
24
pembrolizumab
20
Specimen Handling
19
Temozolomide
16
Surgical Procedures, Operative
14
Magnetic Resonance Spectroscopy
14
Gemcitabine
13
Blood Specimen Collection
13
Biopsy
13
Radiotherapy
12
fludarabine
11
atezolizumab
11
Vincristine
11
Ifosfamide
11
X-Rays
8
Trabectedin
8
Nivolumab
8
Irinotecan
8
Imatinib Mesylate
8
Drug Therapy
8
cabozantinib
7
Surveys and Questionnaires
7
Radiation
6
selinexor
5
liposomal doxorubicin
5
Sunitinib
5
Standard of Care
5
Radiation Dose Hypofractionation
5
Dactinomycin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Trastuzumab
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled